

JESSICA MANDRIOLI

WORK PLACE

University Hospital Modena
Via Pietro Giardini n. 1355, Modena, 41126, Italy Tel:
+390593962546, +393392633246
Mail Jessica.mandrioli@unimore.it
Links: <https://orcid.org/0000-0002-9244-9782>



EDUCATION

1994-2000: University of Modena, Medical School
2000: MD degree, magna cum laude, University of Modena, Italy
2001: Certified as a practicing physician.
2000-2005: Post-degree University School of Neurology
2005: Post-degree in Neurology, magna cum laude, University of Modena, Italy
2007-2008: Medical Statistic Course, University of Modena, Italy
2013: Rasch analysis Course, Bologna, Italy
2015: Specialization Course on bioethics

PROFESSIONAL APPOINTMENTS

2006-2007: Consultant neurologist at the Department of Neuroscience, Azienda USL di Modena, St. Agostino-Estense Hospital, Modena, Italy.
2007- 2021: full timeclinical neurologist at the Department of Neuroscience, Azienda Ospedaliero Universitaria di Modena, St. Agostino-Estense Hospital, Modena, Italy.
2007- present: Chief of Multidisciplinary Centre for MND in Modena, Italy
16 Feb 2021- 15 Mar 2024: Associate Professor in Neurology, University of Modena and Reggio Emilia
15 March 2024 – current: Full Professor in Neurology, University of Modena and Reggio Emilia
01 Apr 2024 - current: Director of the Neurology Unit at AOU Modena
01 Apr 2024 - current: Director of the Neurobiobank of the University of Modena and Reggio Emilia
1 Nov 2024- current: Director Post-graduate school in Neurology, University of Modena and Reggio Emilia

HOST INSTITUTION

Since 2007, she has been in charge of the ALS Center, where she coordinates a multidisciplinary, inter-company team involving multiple specialists dedicated to motor neuron diseases, including pulmonologists, dietitians, speech therapists, psychologists, neuropsychologists, physiatrists, physical therapists, phoniatriests, geneticists, forensic doctors, gastroenterologists, endoscopists, anesthesiologists, and palliative care specialists. She created a provincial network for the comprehensive care of people with ALS and is responsible for the Diagnostic-Therapeutic Care Pathway approved in 2016. The center follows over 350 patients annually (more than 1,000 visits), two-thirds of whom come from outside the province of Modena. The care activities are closely intertwined with research, including through regional, national, and international collaborations. In 2009, she established the regional amyotrophic lateral sclerosis registry, which is still active today, and in 2017 it was recognized as a "registry of regional interest" by REGIONAL LAW June 1, 2017, No. 9.

Together with Prof. Nichelli, Prof. Mandrioli also established the Neurobiobank of Modena, defining a project funded by the Fondazione Cassa di Risparmio di Modena, which now serves the entire Neurology Unit and the Department of Biomedical, Metabolic and Neuroscience Sciences. The Motor Neuron Disease Center in Modena is part of the European consortium ENCALS, which includes the best European centers for ALS care and research, and TRICALS, a European consortium aimed at finding treatments for the disease, particularly through clinical trials. Prof. Mandrioli was elected national coordinator of the Motor Neuron Disease Study Group of the Italian Society of Neurology from 2013 to 2017.

In terms of research, the topics studied include various aspects of ALS, ranging from pathophysiological mechanisms to epidemiology, clinical aspects, biomarker discovery, genetics, environmental factors, and treatments. Prof. Mandrioli has been coordinator of 4 multicenter randomized clinical trials (ERMO-SLA, FETR-ALS, RAP-ALS, CO-ALS) and PI in numerous pharmacological trials for ALS. From an etiological perspective, she contributed to the discovery of the role of the VCP gene in ALS, and in collaboration with international consortia, to the identification of MATR3, C9ORF72, and KIF5A. She has also conducted studies on various environmental factors in ALS and, more recently, on the role of the gut microbiota in the disease.

PATENTS

2022: WO/2022/018771 METHOD FOR DETERMINING A DISEASE PROGRESSION AND SURVIVAL PROGNOSIS FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS. International application number: PCT/IT2020/000057.

SCIENTIFIC APPOINTMENTS

2009- present: Coordinator of the Emilia Romagna Register for Amyotrophic Lateral Sclerosis (4.4 million population).
2013-2017: Coordinator of the Motor Neuron Disease Study Group of the Società Italiana di Neurologia (Italian Neurological Society, SIN).
2002- present: Member of the Società Italiana di Neurologia (SIN)
2008- present: Member of the ITALSGEN Consortium (Italian Consortium for genetic studies on ALS) that discovered many genes associated with ALS (VCP, MATR3, KIF5A, C9ORF72)
2018- 2019: Member of the EAN Scientific Panel Palliative care
2019- present: Member of the EAN Scientific Panel ALS & FTD; Member of ENCALS and TRICALS

TEACHING ACTIVITY

Course in Nervous System Diseases (Master's Degree Program in Medicine and Surgery): from the academic year 2021-2022 to present; includes practical internship teaching activities in Neurology associated with the same course.
Neuroscience Course, "Neurology" Module (Bachelor's Degree Program in Physiotherapy): from the academic year 2020 to 2025.
Neuroscience Course, "Neurology" Module (Bachelor's Degree Program in Speech Therapy): from the academic year 2020 to 2025.
Neuroscience Course, "Neurology" Module (Bachelor's Degree Program in Occupational Therapy): from the academic year 2020 to 2025.
Neuroscience Course, "Neurology" Module (Bachelor's Degree Program in Psychiatric Rehabilitation Techniques): from the academic year 2020 to 2025.
Course in New Developments in Personalized Therapy, "Personalized Medicine in Neurology" Module (Master's Degree Program in Medical Biotechnology): from the academic year 2021-2022 to present.

BIBLIOMETRIC INDICATORS

Scopus:

Documents by author: 204

Citations: 9400

h-index: 51

GRANTS (coordinator)

- **2013–2017** – Regional Government–University Research Program 2011–2012, Clinical Governance Call. *“Effects of motor rehabilitation therapy on disability and quality of life in patients with amyotrophic lateral sclerosis in hospital and home settings.”* **Funding:** €400,000.
- **2015–2021** – AriSLA Ice Bucket Call for Clinical Projects. *“RAP-ALS – Rapamycin (sirolimus) treatment for Amyotrophic Lateral Sclerosis.”* **Funding:** €426,825.
- **2018–2023** – AIFA (Italian Medicines Agency) Call for Independent Research. *“co-ALS – Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial.”* **Funding:** €990,600.
- **2019– 2024**– Italian Ministry of Health, Targeted Research Grant. *“FETR-ALS – Interplay between gut microbiota and adaptive immunity in Amyotrophic Lateral Sclerosis: a clinical trial.”* **Funding:** €432,000.
- **2021–2023** – FAR 2021, UNIMORE Mission-Oriented Interdisciplinary Research Projects Call. *“NEURALS – Enhancing Neuroprotection against neuroinflammation: the role of neurosteroids in Amyotrophic Lateral Sclerosis.”* **Funding:** €64,400.
- **2021–2022** – Roche Clinical Research Call 2021. *“Interaction between gut microbiota and adaptive immunity in Amyotrophic Lateral Sclerosis: a clinical trial.”* **Funding:** €30,000.
- **2023–ongoing** – Italian Ministry of Health, Ordinary Research Projects. *“NEURALSTOP – Neurosteroids against Neuroinflammation: a way to fight Neurodegeneration in Amyotrophic Lateral Sclerosis?”* **Funding:** €432,000.
- **2023 – 2026** – Italian Ministry of Health, PNRR Call. *“GENIALITY – Genetics and Environment iNtersection In the Amyotrophic Lateral Sclerosis–FrontoTemporal Dementia spectrum: an Italian Twins cohort study with a Multi-Omics approach.”* **Funding:** €990,600.
- **2023 – 2026** – Italian Ministry of Research (MIUR), PRIN: Projects of Relevant National Interest. *“MYSTICALS – Microorganisms, Toxins and Immunity InterSection In Amyotrophic Lateral Sclerosis–Frontotemporal Dementia: targeting disease heterogeneity.”* **Funding:** €242,999.
- **2026 –ongoing** – TargetALS Foundation. *“IMPACT-ALS – An AI-driven Multi-omics Platform integrating lipidomics, immune profiling, and inflammatory miRNA signatures to identify actionable therapeutic Targets in ALS.”* **Funding:** \$941,338.

1. Longitudinal CSF and Serum Biomarker Dynamics in Tofersen-Treated SOD1-ALS: A Real-World Multicentre Cohort Study. Giordano A, Mandrioli J, Cerri F, Lunetta C, Saebfar H, Catania M, Battipaglia C, Leone L, Trojsi F, Vizziello M, Gerardi F, Farè M, Zulueta A, Piras R, Giacchino M, Gianferrari G, Dalla Bella E, Domi T, Bonanomi D, Ganci G, Lombardi R, Lauria G, Riva N. *Int J Mol Sci.* 2026 May 9;27(10):4208. doi: 10.3390/ijms27104208.
2. Green space exposure and risk of amyotrophic lateral sclerosis: a population-based case-control study in Northern Italy. Sarti A, Mandrioli J, Costanzini S, Balbo GX, Malagoli C, Martini N, Despini F, Violi F, Malavolti M, Martinelli I, Giacchino M, Donelli G, Canali E, Zinno L, Teggi S, Vinceti M, Filippini T. *Environ Health.* 2026 May 22. doi: 10.1186/s12940-026-01311-w.
3. Circulating Serum Cell-Free Mitochondrial DNA in Amyotrophic Lateral Sclerosis. Zanini G, Martinelli I, Sinigaglia G, Zucchi E, Banchelli F, Simonini C, Gianferrari G, Ghezzi A, Mandrioli J, Pinti M. *Cells.* 2025 Sep 12;14(18):1433. doi: 10.3390/cells14181433.
4. Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation. Hermann DM, Bacigaluppi M, Bassetti CL, Bassotti G, Boltze J, Chan A, Dalkara T, Denes A, Diez-Tejedor E, Dodel R, Doeppner TR, Dzyubenko E, ElAli A, Fulop T, Gerhard A, Giebel B, Gronewold J, Gunzer M, Heinbockel T, Huang K, Iriti M, Karnath HO, Trenite KN, Kilic E, Lanza G, Liesz A, Magnus TU, **Mandrioli J**, Mohamud-Yusuf A, Müller T, Pan S, Peruzzotti-Jametti L, Pluchino S, Pluta R, Popa-Wagner A, Rezayof A, Seghier ML, Shu X, Singh V, Sipilä J, Slevin M, Tang Y, Tsvigoulis G, Varrassi G, Wang C, Yilmaz B, Zaki MS, Zhang J. *Explor Neurosci.* 2025;4:1006106. doi: 10.37349/en.2025.1006106.
5. Patient-centred estimation of multimorbidity in chronic disease populations: a novel approach integrating global burden of disease metrics and healthcare administrative data. Fortuna D, Caselli L, Romoli M, Vignatelli L, Vaudano AE, **Mandrioli J**, Malagù S, Costantini M, Tibaldi G, Gildoni G, Guarino M, Di Pasquale G, Iaboli L, Alberghini L, Fusconi M, Pacilli AMG, Nava S, Mancinelli S, Rolli M. *Popul Health Metr.* 2025 Jul 31;23(1):42. doi: 10.1186/s12963-025-00404-x.
6. Predictors from systemic and neuro-inflammation in amyotrophic lateral sclerosis: A monocentric experience. Martinelli I, Simonini C, Zucchi E, Gianferrari G, Bedin R, Ghezzi A, **Mandrioli J**. *J Neuroimmunol.* 2025 Jul 9;406:578683. doi: 10.1016/j.jneuroim.2025.578683.
7. Exploring the Role of Diabetes in ALS: A Population-Based Cohort Study. Martinelli I, Gianferrari G, Santarelli R, Zucchi E, Simonini C, Fini N, Ghezzi A, Gessani A, Ferri L, Smolik K, Ferraro D, Bedin R, Gizzi M, Sette E, Vacchiano V, Bonan L, Zinno L, De Massis P, Canali E, Medici D, Terlizzi E, Morresi S, Santangelo M, Patuelli A, Currò Dossi M, Longoni M, Pugliatti M, Filippini T, Ferro S, Errals Study Group, **Mandrioli J**. *Life (Basel).* 2025 Jun 10;15(6):936. doi: 10.3390/life15060936.
8. Cortical Excitability as a Prognostic and Phenotypic Stratification Biomarker in Amyotrophic Lateral Sclerosis. Ranieri F, Senerchia G, Bonan L, Casali S, Cabona C, Cantone M, De Marchi F, Diamanti L, Doretti A, Fini N, Filosto M, Fortuna A, Iovino A, Iuzzolino VV, Lanza G, Lunetta C, Maderna L, **Mandrioli J**, Mazzini L, Musumeci G, Nuredini A, Sorarù G, Toriello A, Ticozzi N, Todisco M, Vacchiano V, Zinno L, Silani V, Rossi S, Di Lazzaro V, Dubbio R; MND Study Group of the Italian Neurological Society (SIN) and the Neurostimulation-Neuromodulation Study Group of the Italian Society of Clinical Neurophysiology (SINC). *Ann Neurol.* 2025 Jun 25. doi: 10.1002/ana.27305. Online ahead of print.
9. Exploring NEK1 genetic variability in Italian amyotrophic lateral sclerosis patients. Pensato V, Peverelli S, Tiloca C, Magri S, Brusati A, Pingue M, Morelli C, Dalla Bella E, Manini A, Tannorella P, Doretti A, **Mandrioli J**, Terenghi F, Prella A, Riva N, Verde F, Eleopra R, Taroni F, Lauria Pinter G, Silani V, Ticozzi N, Gellera C, Ratti A. *J Neurol.* 2025 Jun 19;272(7):469. doi: 10.1007/s00415-025-13153-6.
10. Barriers in the Nervous System: Challenges and Opportunities for Novel Biomarkers in Amyotrophic Lateral Sclerosis. Pisoni L, Donini L, Gagni P, Pennuto M, Ratti A, Verde F, Ticozzi N, **Mandrioli J**, Calvo A, Basso M. *Cells.* 2025 Jun 5;14(11):848. doi: 10.3390/cells14110848.
11. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. Verde EM, Secco V, Ghezzi A, **Mandrioli J**, Carra S. *Cells.* 2025 May 8;14(10):680. doi: 10.3390/cells14100680.
12. Phosphatemia is an Independent Prognostic Factor in Amyotrophic Lateral Sclerosis. Vasta R, Koumantakis E, Canosa A, Manera U, Grassano M, Palumbo F, Cabras S, Matteoni E, Di Pedè F, De Mattei F, Vergnano F, **Mandrioli J**, Simonini C, Martinelli I, De Marchi F, Mazzini L, Moglia C, Calvo A, Chiò A. *Ann Neurol.* 2025 Apr 26. doi: 10.1002/ana.27252. Online ahead of print.
13. Healthcare practitioners and robotic-assisted rehabilitation: understanding needs and barriers. Nicora G, Parimbelli E, Mauro MC, Falchini F, Germanotta M, Fasano A, Sgandurra G, Beani E, Gruppioni E, Bugané F, Aprile IG, Quaglini S; Mission 1 Fit4MedRob Consortium. *J Neuroeng Rehabil.* 2025 Apr 9;22(1):78. doi: 10.1186/s12984-025-01593-0.
14. Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen. Simonini C, Zucchi E, Martinelli I, Gianferrari G, Lunetta C, Sorarù G, Trojsi F, Pepe R, Piras R, Giacchino M, Banchelli F, **Mandrioli J**. *Sci Rep.* 2025 Apr 1;15(1):11034. doi: 10.1038/s41598-025-94984-1.
15. Phenotypical Characterization of C9ALS Patients from the Emilia Romagna Registry of ALS: A Retrospective Case-Control Study. Ghezzi A, Gianferrari G, Baldassarri E, Zucchi E, Martinelli I, Vacchiano V, Bonan L, Zinno L, Nuredini A, Canali E, Gizzi M, Terlizzi E, Medici D, Sette E, Currò Dossi M, Morresi S, Santangelo M, Patuelli A, Longoni M, De Massis P, Ferro S, Fini N, Simonini C, Carra S, Zamboni G, **Mandrioli J**. *Genes (Basel).* 2025 Mar 4;16(3):309. doi: 10.3390/genes16030309.
16. Tregs levels and phenotype modifications during Amyotrophic Lateral Sclerosis course. Zucchi E, Banchelli F, Simonini C, De Biasi S, Martinelli I, Gianferrari G, Lo Tartaro D, Cossarizza A, D'Amico R, **Mandrioli J**. *Front Immunol.* 2025 Jan 8;15:1508974. doi: 10.3389/fimmu.2024.1508974. eCollection 2024.
17. Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data. Saez-Atienzar S, Souza CDS, Chia R, Beal SN, Lorenzini I, Huang R, Levy J, Burciu C, Ding J, Gibbs JR, Jones A, Dewan R, Pensato V, Peverelli S, Corrado L, van Vugt JJFA, van Rheenen W, Tunca C, Bayraktar E, Xia M; International ALS Genomics Consortium; ITALSGEN Consortium; SLAGEN Consortium; Project MinE ALS Sequencing Consortium; Iacoangeli A, Shatunov A, Tiloca C, Ticozzi N, Verde F, Mazzini L, Kenna K, Al Khleifat A, Opie-Martin S, Raggi F, Filosto M, Piccinelli SC, Padovani A, Gagliardi S, Inghilleri M, Ferlini A, Vasta R, Calvo A, Moglia C, Canosa A, Manera U, Grassano M, **Mandrioli J**,...

18. Reduced Levels of Neurosteroids in Cerebrospinal Fluid of Amyotrophic Lateral Sclerosis Patients. Lucchi C, Simonini C, Rustichelli C, Avallone R, Zucchi E, Martinelli I, Biagini G, **Mandrioli J**. Biomolecules. 2024 Aug 28;14(9):1076. doi: 10.3390/biom14091076.
19. Altered molecular and cellular mechanisms in KIF5A-associated neurodegenerative or neurodevelopmental disorders. Cozzi M, Magri S, Tedesco B, Patelli G, Ferrari V, Casarotto E, Chierichetti M, Pramaggiore P, Cornaggia L, Piccolella M, Galbiati M, Rusmini P, Crippa V, **Mandrioli J**, Pareyson D, Pisciotto C, D'Arrigo S, Ratti A, Nanetti L, Mariotti C, Sarto E, Pensato V, Gellera C, Di Bella D, Cristofani RM, Taroni F, Poletti A. Cell Death Dis. 2024 Sep 27;15(9):692. doi: 10.1038/s41419-024-07096-5.
20. Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial. Gianferrari G, Cuoghi Costantini R, Crippa V, Carra S, Bonetto V, Pansarasa O, Cereda C, Zucchi E, Martinelli I, Simonini C, Vicini R, Fini N, Trojsi F, Passaniti C, Ticozzi N, Doretti A, Diamanti L, Fiamingo G, Conte A, Dalla Bella E, D'Errico E, Scarian E, Pasetto L, Antoniani F, Galli V, Casarotto E; Co- ALS Investigators Group; D'Amico R, Poletti A, **Mandrioli J**. Brain Commun. 2024 Sep 5;6(5):fcae304. doi: 10.1093/braincomms/fcae304.
21. Trends in Hospital Admissions for Patients with Amyotrophic Lateral Sclerosis: Insights from a Retrospective Cohort Study in a Province in Northern Italy. Gianferrari G, Zucchi E, Martinelli I, Simonini C, Fini N, Ferro S, Mercati A, Ferri L, Filippini T, Vinceti M, **Mandrioli J**. Life (Basel). 2024 Jul 27;14(8):941. doi: 10.3390/life14080941.
22. Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis. Pupillo E, Bianchi E, Bonetto V, Pasetto L, Bendotti C, Paganoni S, **Mandrioli J**, Mazzini L; RNS60-ALS Study Group. Brain Behav Immun. 2024 Nov;122:456-462. doi: 10.1016/j.bbi.2024.08.044.
23. Changes in Cerebrospinal Fluid Concentrations of Selenium Species Induced by Tofersen Administration in Subjects with Amyotrophic Lateral Sclerosis Carrying SOD1 Gene Mutations. Vinceti M, Urbano T, Filippini T, Bedin R, Simonini C, Sorarù G, Trojsi F, Michalke B, **Mandrioli J**. Biol Trace Elem Res. 2024 Jul 17. doi: 10.1007/s12011-024-04311-4.
24. Multifaceted superoxide dismutase 1 expression in amyotrophic lateral sclerosis patients: a rare occurrence? Martinelli I, **Mandrioli J**, Ghezzi A, Zucchi E, Gianferrari G, Simonini C, Cavallieri F, Valzania F. Neural Regen Res. 2025 Jan 1;20(1):130-138. doi: 10.4103/NRR.NRR-D- 23-01904.
25. Amyotrophic lateral sclerosis stratification: unveiling patterns with virome, inflammation, and metabolism molecules. Niccolai E, Pedone M, Martinelli I, Nannini G, Baldi S, Simonini C, Di Gloria L, Zucchi E, Ramazzotti M, Spezia PG, Maggi F, Quaranta G, Masucci L, Bartolucci G, Stingo FC, **Mandrioli J**, Amedei A. J Neurol. 2024 Jul;271(7):4310-4325. doi: 10.1007/s00415-024-12348-7.
26. Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis: Clinical Protocol and Evaluation of Microbiota Immunity Axis. Niccolai E, Martinelli I, Quaranta G, Nannini G, Zucchi E, De Maio F, Gianferrari G, Bibbò S, Cammarota G, **Mandrioli J**, Masucci L, Amedei A. Methods Mol Biol. 2024;2761:373-396. doi: 10.1007/978-1-0716-3662-6_27.
27. Therapeutic potential of stilbenes in neuropsychiatric and neurological disorders: A comprehensive review of preclinical and clinical evidence. Socala K, Żmudzka E, Lustyk K, Zagaja M, Brighenti V, Costa AM, Andres-Mach M, Pytko K, Martinelli I, **Mandrioli J**, Pellati F, Biagini G, Wlaź P. Phytother Res. 2024 Mar;38(3):1400-1461. doi: 10.1002/ptr.8101. Epub 2024 Jan 17.
28. The association between lifelong personality and clinical phenotype in the FTD-ALS spectrum. Vinceti G, Carbone C, Galligani C, Fiondella L, Salemme S, Zucchi E, Martinelli I, Gianferrari G, Tondelli M, **Mandrioli J**, Chiari A, Zamboni G. Front Neurosci. 2023 Oct 4;17:1248622. doi: 10.3389/fnins.2023.1248622
29. Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study. Zucchi E, Musazzi UM, Fedele G, Martinelli I, Gianferrari G, Simonini C, Fini N, Ghezzi A, Caputo M, Sette E, Vacchiano V, Zinno L, Anceschi P, Canali E, Vinceti M, Ferro S, **Mandrioli J**; ERRALS study group. EClinicalMedicine. 2023 Oct 5;65:102256. doi: 10.1016/j.eclinm.2023.102256.
30. SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study. Martinelli I, Zucchi E, Simonini C, Gianferrari G, Bedin R, Biral C, Ghezzi A, Fini N, Carra S, **Mandrioli J**. Eur J Neurol. 2024 Jan;31(1):e16054. doi: 10.1111/ene.16054.
31. Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries. Martinelli I, Ghezzi A, Zucchi E, Gianferrari G, Ferri L, Moglia C, Manera U, Solero L, Vasta R, Canosa A, Grassano M, Brunetti M, Mazzini L, De Marchi F, Simonini C, Fini N, Vinceti M, Pinti M, Chiò A, Calvo A, **Mandrioli J**. J Neurol. 2023 Dec;270(12):6081-6092. doi: 10.1007/s00415- 023-11963-0.
32. Interplay of Metallome and Metabolome in Amyotrophic Lateral Sclerosis: A Study on Cerebrospinal Fluid of Patients Carrying Disease- Related Gene Mutations. Solovyev N, Lucio M, **Mandrioli J**, Forcisi S, Kanawati B, Uhl J, Vinceti M, Schmitt-Kopplin P, Michalke B. ACS Chem Neurosci. 2023 Sep 6;14(17):3035-3046. doi: 10.1021/acscchemneuro.3c00128. Epub 2023 Aug 22.
33. Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. **Mandrioli J**, D'Amico R, Zucchi E, De Biasi S, Banchelli F, Martinelli I, Simonini C, Lo Tartaro D, Vicini R, Fini N, Gianferrari G, Pinti M, Lunetta C, Gerardi F, Tarlarini C, Mazzini L, De Marchi F, Scognamiglio A, Sorarù G, Fortuna A, Lauria G, Bella ED, Caponnetto C, Meo G, Chio A, Calvo A, Cossarizza A. Nat Commun. 2023 Aug 17;14(1):4970. doi: 10.1038/s41467-023-40734-8.
34. Withdrawal of mechanical ventilation in amyotrophic lateral sclerosis patients: a multicenter Italian survey. Moglia C, Palumbo F, Veronese S; M. N. D. Italian Study Group; Calvo A. Neurol Sci. 2023 Dec;44(12):4349-4357. doi: 10.1007/s10072-023-06905-7.
35. Retrospective observational study on the use of acetyl-L-carnitine in ALS. Sassi S, Bianchi E, Diamanti L, Tornabene D, Sette E, Medici D, Matà S, Leccese D, Sperti M, Martinelli I, Ghezzi A, **Mandrioli J**, Iuzzolino VV, Dubbioso R, Trojsi F, Passaniti C, D'Alvano G, Filosto M, Padovani A, Mazzini L, De Marchi F, Zinno L, Nuredini A, Bongioanni P, Dolciotti C, Canali E, Toschi G, Petrucci A, Perna A, Riso V, Inghilleri M, Libonati L, Cambieri C, Pupillo E. J Neurol. 2023 Nov;270(11):5344-5357. doi: 10.1007/s00415-023-11844-6.
36. Insight into Elderly ALS Patients in the Emilia Romagna Region: Epidemiological and Clinical Features of Late-Onset ALS in a Prospective, Population-Based Study. Gianferrari G, Martinelli I, Simonini C, Zucchi E, Fini N, Caputo M, Ghezzi A, Gessani A, Canali E, Casmiro M, De Massis P, Curro' Dossi M, De Pasqua S, Liguori R, Longoni M, Medici D, Morresi S, Patuelli A, Pugliatti M, Santangelo M, Sette E, Stragliati F, Terlizzi E, Vacchiano V, Zinno L, Ferro S, Amedei A, Filippini T, Vinceti M, Errals Group, **Mandrioli J**. Life (Basel). 2023 Apr 3;13(4):942. doi: 10.3390/life13040942.

37. Young Onset Alzheimer's Disease Associated with C9ORF72 Hexanucleotide Expansion: Further Evidence for a Still Unsolved Association. Vinceti G, Galligani C, Zucchi E, Martinelli I, Gianferrari G, Simonini C, Bedin R, Chiari A, Zamboni G, **Mandrioli J**. *Genes (Basel)*. 2023 Apr 17;14(4):930. doi: 10.3390/genes14040930.
38. Human Microglia Synthesize Neurosteroids to Cope with Rotenone-Induced Oxidative Stress. Lucchi C, Codeluppi A, Filaferro M, Vitale G, Rustichelli C, Avallone R, **Mandrioli J**, Biagini G. *Antioxidants (Basel)*. 2023 Apr 19;12(4):963. doi: 10.3390/antiox12040963.
39. Targeting the NEDP1 enzyme to ameliorate ALS phenotypes through stress granule disassembly. Kassouf T, Shrivastava R, Meszka I, Bailly A, Polanowska J, Trauchessec H, **Mandrioli J**, Carra S, Xirodimas DP. *Sci Adv*. 2023 Mar 31;9(13):eabq7585. doi: 10.1126/sciadv.abq7585.
40. The HFE p.H63D (p.His63Asp) Polymorphism Is a Modifier of ALS Outcome in Italian and French Patients with SOD1 Mutations. Canosa A, Calvo A, Mora G, Moglia C, Brunetti M, Barberis M, Borghero G, Caponnetto C, Trojsi F, Spataro R, Volanti P, Simone IL, Salvi F, Logullo FO, Riva N, Tremolizzo L, Giannini F, **Mandrioli J**, Tanel R, Murru MR, Mandich P, Conforti FL, Zollino M, Sabatelli M, Tarlarini C, Lunetta C, Mazzini L, D'Alfonso S, Guy N, Meininger V, Clavelou P, Camu W, Chiò A, On Behalf Of Italsgen Consortium. *Biomedicines*. 2023 Feb 24;11(3):704. doi: 10.3390/biomedicines11030704.
41. The landscape of cognitive impairment in superoxide dismutase 1-amyotrophic lateral sclerosis. Martinelli I, Zucchi E, Simonini C, Gianferrari G, Zamboni G, Pinti M, **Mandrioli J**. *Neural Regen Res*. 2023 Jul;18(7):1427-1433. doi: 10.4103/1673-5374.361535.
42. Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS): validation and longitudinal performance. Fortuna A, Sabbatini D, Frigo A, Bello L, Calvi F, Blasi L, Gianferrari G, Martinelli I, Minicuci G, Pegoraro E, **Mandrioli J**, Sorarù G. *J Neurol*. 2023 Mar;270(3):1452-1456. doi: 10.1007/s00415-022-11483-3.
43. Factors predicting disease progression in C9ORF72 ALS patients. **Mandrioli J**, Zucchi E, Martinelli I, Van der Most L, Gianferrari G, Moglia C, Manera U, Solero L, Vasta R, Canosa A, Grassano M, Brunetti M, Mazzini L, De Marchi F, Simonini C, Fini N, Tupler R, Vinceti M, Chiò A, Calvo A. *J Neurol*. 2023 Feb;270(2):877-890. doi: 10.1007/s00415-022-11426-y.
44. Mitochondrial and Endoplasmic Reticulum Alterations in a Case of Amyotrophic Lateral Sclerosis Caused by TDP-43 A382T Mutation. Zanini G, Sella V, Nasi M, De Gaetano A, Martinelli I, Gianferrari G, Lofaro FD, Boraldi F, **Mandrioli J**, Pinti M. *Int J Mol Sci*. 2022 Oct 6;23(19):11881. doi: 10.3390/ijms231911881.
45. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Beghi E, Pupillo E, Bianchi E, Bonetto V, Luotti S, Pasetto L, Bendotti C, Tortarolo M, Sironi F, Camporeale L, Sherman AV, Paganoni S, Scognamiglio A, De Marchi F, Bongioanni P, Del Carratore R, Caponnetto C, Diamanti L, Martinelli D, Calvo A, Filosto M, Padovani A, Piccinelli SC, Ricci C, Dalla Giacomina S, De Angelis N, Inghilleri M, Spataro R, La Bella V, Logroscino G, Lunetta C, Tarlarini C, **Mandrioli J**, Martinelli I, Simonini C, Zucchi E, Monsurro MR, Ricciardi D, Trojsi F, Riva N, Filippi M, Simone IL, Sorarù G, Spera C, Florio L, Messina S, Russo M, Siciliano G, Conte A, Saggi MV, Carboni N, Mazzini L; RNS60-ALS Study Group. *Eur J Neurol*. 2023 Jan;30(1):69-86. doi: 10.1111/ene.15573.
46. Selenoprotein P Concentrations in the Cerebrospinal Fluid and Serum of Individuals Affected by Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment and Alzheimer's Dementia. Urbano T, Vinceti M, **Mandrioli J**, Chiari A, Filippini T, Bedin R, Tondelli M, Simonini C, Zamboni G, Shimizu M, Saito Y. *Int J Mol Sci*. 2022 Aug 30;23(17):9865. doi: 10.3390/ijms23179865.
47. G507D mutation in FUS gene causes familial amyotrophic lateral sclerosis with a specific genotype-phenotype correlation. Martinelli I, Zucchi E, Pensato V, Gellera C, Traynor BJ, Gianferrari G, Chiò A, **Mandrioli J**. *Neurobiol Aging*. 2022 Oct;118:124-128. doi: 10.1016/j.neurobiolaging.2022.05.006.
48. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggressive disease phenotype. Ghezzi A, Martinelli I, Carra S, Mediani L, Zucchi E, Simonini C, Gianferrari G, Fini N, Cereda C, Gellera C, Pensato V, **Mandrioli J**. *Neurol Sci*. 2022 Oct;43(10):6087-6090. doi: 10.1007/s10072-022-06229-y.
49. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Gaimari A, Fusaroli M, Raschi E, Baldin E, Vignatelli L, Nonino F, De Ponti F, **Mandrioli J**, Poluzzi E. *Drug Saf*. 2022 Jun;45(6):663-673. doi: 10.1007/s40264-022-01184-1.
50. Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy. Gianferrari G, Martinelli I, Zucchi E, Simonini C, Fini N, Vinceti M, Ferro S, Gessani A, Canali E, Valzania F, Sette E, Pugliatti M, Tugnoli V, Zinno L, Stano S, Santangelo M, De Pasqua S, Terlizzi E, Guidetti D, Medici D, Salvi F, Liguori R, Vacchiano V, Casmiro M, Querzani P, Currò Dossi M, Patuelli A, Morresi S, Longoni M, De Massis P, Rinaldi R, Borghi A, Errals Group, Amedei A, **Mandrioli J**. *Biomedicines*. 2022 Mar 31;10(4):819. doi: 10.3390/biomedicines10040819.
51. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. Faghri F, Brunn F, Dadu A; PARALS consortium; ERRALS consortium; Zucchi E, Martinelli I, Mazzini L, Vasta R, Canosa A, Moglia C, Calvo A, Nalls MA, Campbell RH, **Mandrioli J**, Traynor BJ, Chiò A. *Lancet Digit Health*. 2022 May;4(5):e359-e369. doi: 10.1016/S2589-7500(21)00274-0. Epub 2022 Mar 24.
52. The Potential Role of Peripheral Oxidative Stress on the Neurovascular Unit in Amyotrophic Lateral Sclerosis Pathogenesis: A Preliminary Report from Human and In Vitro Evaluations. Grossini E, Garhwal D, Venkatesan S, Ferrante D, Mele A, Saraceno M, Scognamiglio A, **Mandrioli J**, Amedei A, De Marchi F, Mazzini L. *Biomedicines*. 2022 Mar 17;10(3):691. doi: 10.3390/biomedicines10030691.
53. Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. Tavazzi E, Daberdaku S, Zandonà A, Vasta R, Nefussy B, Lunetta C, Mora G, **Mandrioli J**, Grisan E, Tarlarini C, Calvo A, Moglia C, Drory V, Gotkine M, Chiò A, Di Camillo B; Piemonte, Valle d'Aosta Register for ALS (PARALS), for the Emilia Romagna Registry for ALS (ERRALS). *J Neurol*. 2022 Jul;269(7):3858-3878. doi: 10.1007/s00415-022-11022-0.
54. Neutrophils-to-Lymphocyte Ratio Is Associated with Progression and Overall Survival in Amyotrophic Lateral Sclerosis. Leone MA, **Mandrioli J**, Russo S, Cucovici A, Gianferrari G, Lisnic V, Muresanu DF, Giuliani F, Copetti M, The Pooled Resource Open-Access Als Clinical Trials Consortium, Fontana A. *Biomedicines*. 2022 Feb 1;10(2):354. doi: 10.3390/biomedicines10020354.
55. Clinical trials in pediatric ALS: a TRICALS feasibility study. Kliest T, Van Eijk RPA, Al-Chalabi A, Albanese A, Andersen PM, Amador MDM, Bråthen G, Brunaud-Danel V, Brylev L, Camu W, De Carvalho M, Cereda C, Cetin H, Chaverri D, Chiò A, Corcia P, Couratier P, De Marchi F, Desnuelle C, Van Es MA, Esteban J, Filosto M, García Redondo A, Grosskreutz J, Hanemann CO, Holmø T, Høyer H, Ingre C, Koritnik B, Kuzma-Kozakiewicz M, Lambert T, Leigh PN, Lunetta C, **Mandrioli J**, McDermott CJ, Meyer T, Mora JS, Petri S, Povedano M, Reviers E, Riva N, Roes KCB, Rubio MÁ,

- Salachas F, Sarafov S, Sorarù G, Stevic Z, Svenstrup K, Møller AT, Turner MR, Van Damme P, Van Leeuwen LAG, Varona L, Vázquez Costa JF, Weber M, Hardiman O, Van Den Berg LH. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):481-488. doi: 10.1080/21678421.2021.2024856.
56. Validation of the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire for the evaluation of dysphagia in ALS patients. Diamanti L, Borrelli P, Dubbioso R, Capasso M, Morelli C, Lunetta C, Petrucci A, Mora G, Volanti P, Inghilleri M, Tremolizzo L, **Mandrioli J**, Mazzini L, Vedovello M, Siciliano G, Filosto M, Matà S, Montomoli C; DYALS Study Group. *Neurol Sci*. 2022 May;43(5):3195-3200. doi: 10.1007/s10072-021-05775-1.
 57. CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement. Simonini C, Zucchi E, Bedin R, Martinelli I, Gianferrari G, Fini N, Sorarù G, Liguori R, Vacchiano V, **Mandrioli J**. *Biomedicines*. 2021 Nov 5;9(11):1623. doi: 10.3390/biomedicines9111623.
 58. Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus. Giovannini G, Bedin R, Ferraro D, Vaudano AE, **Mandrioli J**, Meletti S. *Epilepsia*. 2022 Jan;63(1):e23-e29. doi: 10.1111/epi.17132.
 59. Duplication of exons 15 and 16 in Matrin-3: a phenotype bridging amyotrophic lateral sclerosis and immune-mediated disorders. Caputo M, Zucchi E, Martinelli I, Gianferrari G, Simonini C, Amedei A, Nicolai E, Gellera C, Pensato V, **Mandrioli J**. *Neurol Sci*. 2022 Feb;43(2):1419- 1421. doi: 10.1007/s10072-021-05669-2.
 60. Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. Johnson JO, Chia R, Miller DE, Li R, Kumaran R, Abramzon Y, Alahmady N, Renton AE, Topp SD, Gibbs JR, Cookson MR, Sabir MS, Dalgard CL, Troakes C, Jones AR, Shatunov A, Iacoangeli A, Al Khleifat A, Ticozzi N, Silani V, Gellera C, Blair IP, Dobson-Stone C, Kwok JB, Bonkowski ES, Palvadeau R, Tienari PJ, Morrison KE, Shaw PJ, Al-Chalabi A, Brown RH Jr, Calvo A, Mora G, Al-Saif H, Gotkine M, Leigh F, Chang JJ, Perlman SJ, Glass I, Scott AI, Shaw CE, Basak AN, Landers JE, Chiò A, Crawford TO, Smith BN, Traynor BJ; FALS Sequencing Consortium; American Genome Center; International ALS Genomics Consortium; and ITALSGEN Consortium; Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp SD, Scotter EL, Kenna KP, Keagle P, Tiloca C, Vance C, Troakes C, Colombrita C, King A, Pensato V, Castellotti B, Baas F, Ten Asbroek ALMA, McKenna-Yasek D, McLaughlin RL, Polak M, Asress S, Esteban-Pérez J, Stevic Z, D'Alfonso S, Mazzini L, Comi GP, Del Bo R, Ceroni M, Gagliardi S, Querin G, Bertolin C, van Rheenen W, Rademakers R, van Blitterswijk M, Lauria G, Duga S, Corti S, Cereda C, Corrado L, Sorarù G, Williams KL, Nicholson GA, Blair IP, Leblond-Manry C, Rouleau GA, Hardiman O, Morrison KE, Veldink JH, van ... *JAMA Neurol*. 2021 Oct 1;78(10):1236-1248. doi: 10.1001/jamaneurol.2021.2598.
 61. Coffee and Tea Consumption Impact on Amyotrophic Lateral Sclerosis Progression: A Multicenter Cross-Sectional Study. Cucovici A, Ivashynka A, Fontana A, Russo S, Mazzini L, **Mandrioli J**, Lisnic V, Muresanu DF, Leone MA. *Front Neurol*. 2021 Jul 28;12:637939. doi: 10.3389/fneur.2021.637939.
 62. Evaluation of peripherin in biofluids of patients with motor neuron diseases. Sabbatini D, Raggi F, Ruggero S, Seguso M, **Mandrioli J**, Cagnin A, Briani C, Toffanin E, Gizzi M, Fortuna A, Bello L, Pegoraro E, Musso G, Sorarù G. *Ann Clin Transl Neurol*. 2021 Aug;8(8):1750-1754. doi: 10.1002/acn3.51419.
 63. The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity? Nicolai E, Di Pilato V, Nannini G, Baldi S, Russo E, Zucchi E, Martinelli I, Menicatti M, Bartolucci G, **Mandrioli J**, Amedei A. *Biomedicines*. 2021 Jun 29;9(7):753. doi: 10.3390/biomedicines9070753.
 64. The Impact of Lifetime Alcohol and Cigarette Smoking Loads on Amyotrophic Lateral Sclerosis Progression: A Cross-Sectional Study. Cucovici A, Fontana A, Ivashynka A, Russo S, Renna V, Mazzini L, Gagliardi I, **Mandrioli J**, Martinelli I, Lisnic V, Muresanu DF, Zarrelli M, Copetti M, Leone MA. *Life (Basel)*. 2021 Apr 17;11(4):352. doi: 10.3390/life11040352.
 65. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Dalla Bella E, Bersano E, Antonini G, Borghero G, Capasso M, Caponnetto C, Chiò A, Corbo M, Filosto M, Giannini F, Spataro R, Lunetta C, **Mandrioli J**, Messina S, Monsurro MR, Mora G, Riva N, Rizzi R, Siciliano G, Silani V, Simone I, Sorarù G, Tugnoli V, Verriello L, Volanti P, Furlan R, Nolan JM, Abgueguen E, Tramacere I, Lauria G. *Brain*. 2021 Oct 22;144(9):2635-2647. doi: 10.1093/brain/awab167.
 66. Hsp90-mediated regulation of DYRK3 couples stress granule disassembly and growth via mTORC1 signaling. Mediani L, Antoniani F, Galli V, Vinet J, Carrà AD, Bigi I, Tripathy V, Tiago T, Cimino M, Leo G, Amen T, Kaganovich D, Cereda C, Pansarasa O, **Mandrioli J**, Tripathi P, Troost D, Aronica E, Buchner J, Goswami A, Sterneckert J, Alberti S, Carra S. *EMBO Rep*. 2021 May 5;22(5):e51740. doi: 10.15252/embr.202051740.
 67. Risk of Amyotrophic Lateral Sclerosis and Exposure to Particulate Matter from Vehicular Traffic: A Case-Control Study. Filippini T, **Mandrioli J**, Malagoli C, Costanzini S, Cherubini A, Maffei G, Vinceti M. *Int J Environ Res Public Health*. 2021 Jan 22;18(3):973. doi: 10.3390/ijerph18030973.
 68. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Zucchi E, Bonetto V, Sorarù G, Martinelli I, Parchi P, Liguori R, **Mandrioli J**. *Mol Neurodegener*. 2020 Oct 15;15(1):58. doi: 10.1186/s13024-020-00406-3.
 69. BAG3 and BAG6 differentially affect the dynamics of stress granules by targeting distinct subsets of defective polypeptides released from ribosomes. Mediani L, Galli V, Carrà AD, Bigi I, Vinet J, Ganassi M, Antoniani F, Tiago T, Cimino M, Mateju D, Cereda C, Pansarasa O, Alberti S, **Mandrioli J**, Carra S. *Cell Stress Chaperones*. 2020 Nov;25(6):1045-1058. doi: 10.1007/s12192-020-01141-w.
 70. Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. Schito P, Ceccardi G, Calvo A, Falzone YM, Moglia C, Lunetta C, Marinou K, Ticozzi N, Scialo C, Sorarù G, Trojsi F, Conte A, Tortelli R, Russo M, Zucchi E, Pozzi L, Domi T, Carrera P, Agosta F, Quattrini A, Fazio R, Chiò A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Tedeschi G, Sabatelli M, Logroscino G, Messina S, **Mandrioli J**, Riva N, Filippi M. *J Neurol Neurosurg Psychiatry*. 2020 Sep;91(9):1001-1003. doi: 10.1136/jnnp-2020-323542.
 71. Tetrodotoxin-Sensitive Neuronal-Type Na⁺ Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. Munger MA, Olğar Y, Koleske ML, Struckman HL, **Mandrioli J**, Lou Q, Bonila I, Kim K, Ramos Mondragon R, Priori SG, Volpe P, Valdivia HH, Biskupiak J, Carnes CA, Veeraraghavan R, Györke S, Radwański PB. *J Am Heart Assoc*. 2020 Jun 2;9(11):e015119. doi: 10.1161/JAHA.119.015119.
 72. The study of levels from redox-active elements in cerebrospinal fluid of amyotrophic lateral sclerosis patients carrying disease-related gene mutations shows potential copper dyshomeostasis. Violi F, Solovyev N, Vinceti M, **Mandrioli J**, Lucio M, Michalke B. *Metallomics*. 2020 May 27;12(5):668-681. doi: 10.1039/d0mt00051e.
 73. Living near waterbodies as a proxy of cyanobacteria exposure and risk of amyotrophic lateral sclerosis: a population based case-control study. Fiore M, Parisio R, Filippini T, Mantione V, Platania A, Odone A, Signorelli C, Pietrini V, **Mandrioli J**, Teggi S, Costanzini S, Antonio C, Zuccarello P, Oliveri Conti G, Nicoletti A, Zappia M, Vinceti M, Ferrante M. *Environ Res*. 2020 Jul;186:109530. doi: 10.1016/j.envres.2020.109530.

74. Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. Filippini T, Tesaro M, Fiore M, Malagoli C, Consonni M, Violi F, Iacuzio L, Arcolin E, Oliveri Conti G, Cristaldi A, Zuccarello P, Zucchi E, Mazzini L, Pisano F, Gagliardi I, Patti F, **Mandrioli J**, Ferrante M, Vinceti M. *Int J Environ Res Public Health*. 2020 Apr 22;17(8):2882. doi: 10.3390/ijerph17082882.
75. The NGS technology for the identification of genes associated with the ALS. A systematic review. Pecoraro V, **Mandrioli J**, Carone C, Chiò A, Traynor BJ, Trenti T. *Eur J Clin Invest*. 2020 May;50(5):e13228. doi: 10.1111/eci.13228.
76. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). Salamone P, Fuda G, Casale F, Marrali G, Lunetta C, Caponnetto C, Mazzini L, La Bella V, **Mandrioli J**, Simone IL, Moglia C, Calvo A, Tarella C, Chio A; STEMALS-II Study Group. *BMJ Open*. 2020 Mar 24;10(3):e034049. doi: 10.1136/bmjopen-2019-034049.
77. Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. Filippini T, Fiore M, Tesaro M, Malagoli C, Consonni M, Violi F, Arcolin E, Iacuzio L, Oliveri Conti G, Cristaldi A, Zuccarello P, Zucchi E, Mazzini L, Pisano F, Gagliardi I, Patti F, **Mandrioli J**, Ferrante M, Vinceti M. *Int J Environ Res Public Health*. 2020 Jan 30;17(3):857. doi: 10.3390/ijerph17030857.
78. Amyotrophic lateral sclerosis incidence following exposure to inorganic selenium in drinking water: A long-term follow-up. Vinceti M, Filippini T, Malagoli C, Violi F, **Mandrioli J**, Consonni D, Rothman KJ, Wise LA. *Environ Res*. 2019 Dec;179(Pt A):108742. doi: 10.1016/j.envres.2019.108742.
79. FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. **Mandrioli J**, Amedei A, Cammarota G, Niccolai E, Zucchi E, D'Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. *Front Neurol*. 2019 Sep 20;10:1021. doi: 10.3389/fneur.2019.01021.
80. Influence of selenium on the emergence of neuro tubule defects in a neuron-like cell line and its implications for amyotrophic lateral sclerosis. Maraldi T, Beretti F, Anselmi L, Franchin C, Arrigoni G, Braglia L, **Mandrioli J**, Vinceti M, Marmiroli S. *Neurotoxicology*. 2019 Dec;75:209-220. doi: 10.1016/j.neuro.2019.09.015.
81. Serial ultrasound assessment of diaphragmatic function and clinical outcome in patients with amyotrophic lateral sclerosis. Fantini R, Tonelli R, Castaniere I, Tabbi L, Pellegrino MR, Cerri S, Livrieri F, Giaroni F, Monelli M, Ruggieri V, Fini N, **Mandrioli J**, Clini E, Marchioni A. *BMC Pulm Med*. 2019 Aug 27;19(1):160. doi: 10.1186/s12890-019-0924-5.
82. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, **Mandrioli J**, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O; AB10015 STUDY GROUP. *Amyotroph Lateral Scler Frontotemporal Degener*. 2020 Feb;21(1-2):5-14. doi: 10.1080/21678421.2019.1632346
83. ALS and FTD: Where RNA metabolism meets protein quality control. **Mandrioli J**, Mediani L, Alberti S, Carra S. *Semin Cell Dev Biol*. 2020 Mar;99:183-192. doi: 10.1016/j.semcdb.2019.06.003.
84. Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurro MR, Tedeschi G, **Mandrioli J**. *Front Neurosci*. 2019 May 17;13:485. doi: 10.3389/fnins.2019.00485.
85. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). **Mandrioli J**, Crippa V, Cereda C, Bonetto V, Zucchi E, Gessani A, Ceroni M, Chio A, D'Amico R, Monsurro MR, Riva N, Sabatelli M, Silani V, Simone IL, Sorarù G, Provenzano A, D'Agostino VG, Carra S, Poletti A. *BMJ Open*. 2019 May 30;9(5):e028486. doi: 10.1136/bmjopen-2018-028486.
86. High-frequency motor rehabilitation in amyotrophic lateral sclerosis: a randomized clinical trial. Zucchi E, Vinceti M, Malagoli C, Fini N, Gessani A, Fasano A, Rizzi R, Sette E, Cavazza S, Flocchi A, Buja S, Faccioli T, Storani S, **Mandrioli J**. *Ann Clin Transl Neurol*. 2019 Mar 18;6(5):893-901. doi: 10.1002/acn3.765.
87. Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder. Zucchi E, Ticozzi N, **Mandrioli J**. *Front Neurosci*. 2019 Mar 11;13:175. doi: 10.3389/fnins.2019.00175.
88. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G; ITALSGEN Consortium; International ALS Genomics Consortium; Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chiò A, Traynor BJ. *Ann Neurol*. 2019 Apr;85(4):470-481. doi: 10.1002/ana.25431.

La sottoscritta esprime il proprio consenso affinché i dati personali forniti possano essere trattati nel rispetto del D.lgs n.196/03, per gli adempimenti connessi alla presente procedura.

Modena, 11 July 2026

Firma

